TransGenic Group

TransGenic Group Forward P/E

The Forward P/E Ratio of TransGenic Group (2342.T) as of Nov 18, 2026 is -65.92. In the previous year, Forward P/E Ratio was -4.67 — a change of 1,310.21% (lower).

Forward P/E

-65.92

YoY

1,310.21%

Last updated:

Forward P/E Ratio of TransGenic Group is 2026 -65.92 . Forward P/E Ratio of TransGenic Group was 2025 -4.67 . It decreases by 1,310.21% lower compared to the previous year.

The TransGenic Group Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
25.19 JPY
Jan 1, 2020
-11.56 JPY
Jan 1, 2021
9.32 JPY
Jan 1, 2022
2.71 JPY
Jan 1, 2023
-12.43 JPY
Jan 1, 2024
1,246.94 JPY
Jan 1, 2025
-4.67 JPY
Jan 1, 2026
-65.92 JPY
The TransGenic Group Forward P/E history
YEARForward P/EYoY
-65.92+1,310.21%
-4.67-100.37%
1,246.94-10,128.59%
-12.43-558.01%
2.71-70.89%
9.32-180.67%
-11.56-145.88%
25.19-89.67%
243.74+286.13%
63.12-81.92%
349.20+22.19%
285.78-737.58%
-44.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Forward P/E Ratio of TransGenic Group is -65.92 in 2026.

Forward P/E Ratio of TransGenic Group changed from -4.67 to -65.92, representing a 1,310.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's TransGenic Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TransGenic Group

All Key Metrics — TransGenic Group